Focus: Avalyn Pharmaceuticals is a public-stage biotech company focused on therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, operating as a lean 1-50 person organization from Cambridge, MA.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Best suited for early-stage operators and mission-driven scientists willing to accept structural risk for meaningful IPF/PF research impact in a lean, capital-efficient setting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Avalyn Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Avalyn Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
AVLN SEC Filings - AVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
AVLN SEC Filings - AVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms Stock Titan
Director Kate Haviland receives 26,978 Avalyn Pharma (AVLN) stock options at $18 - Stock Titan
Director Kate Haviland receives 26,978 Avalyn Pharma (AVLN) stock options at $18 Stock Titan
Erin Lavelle awarded 26,978 Avalyn Pharma (AVLN) stock options at $18 - Stock Titan
Erin Lavelle awarded 26,978 Avalyn Pharma (AVLN) stock options at $18 Stock Titan
[CERT] Avalyn Pharma Inc. Certification Filing | AVLN SEC Filing - Form CERT - Stock Titan
[CERT] Avalyn Pharma Inc. Certification Filing | AVLN SEC Filing - Form CERT Stock Titan
Biotech veteran behind Mineralys joins Avalyn board as Phase 2 programs advance - Stock Titan
Biotech veteran behind Mineralys joins Avalyn board as Phase 2 programs advance Stock Titan
AVLN Stock Price, News & Analysis - Stock Titan
AVLN Stock Price, News & Analysis Stock Titan
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo